Quote | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Last: | $2.62 |
---|---|
Change Percent: | 0.72% |
Open: | $2.74 |
Close: | $2.62 |
High: | $2.74 |
Low: | $2.55 |
Volume: | 123,286 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potentia...
Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration ...
Message Board Posts | Lexaria Bioscience Corp. (NASDAQ:LEXX)
Subject | By | Source | When |
---|---|---|---|
Dont get too excited down 11% pre market | PotsandPans420 | investorshub | 05/19/2023 12:18:24 PM |
Hope Springs Eternal! | Shawking | investorshub | 05/19/2023 4:33:47 AM |
Be interesting to see if we see any | PotsandPans420 | investorshub | 05/18/2023 8:09:02 PM |
https://www.globenewswire.com/en/news-release/2021/02/23/2180141/28124/en/Global | Shawking | investorshub | 05/18/2023 7:45:25 PM |
Rush of price activity and volume more news coming? | codfather | investorshub | 05/18/2023 6:00:14 PM |
News, Short Squeeze, Breakout and More Instantly...
Lexaria Bioscience Corp. Company Name:
LEXX Stock Symbol:
NASDAQ Market:
Lexaria Bioscience Corp. Website:
Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, is doubling down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. “The company is optimistic that the studies will yield positive results, not just in the potentia...
Lexaria, a global innovator in drug delivery platforms, has announced the successful completion of its second round of dosing for its human pilot study #2 The final study arm is set for completion in early July, and if successful, it will help remedy the downsides of swallowed administration ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to oversee execution of the company’s 12-week chronic study GLP-1-H24-4. The study will evaluate various DehydraTECH...